NEW YORK (Reuters)—Generic drug makers are turning to mergers and acquisitions to shield themselves against a concerted effort by U.S. regulators to crack down on steep drug prices. Impax Laboratories Inc, Perrigo Company Plc and Alvogen Inc have been talking to advisers about strategic options for their generics businesses, ranging from acquisitions to increase scale…
Search results for: drug prices
Japan PM’s Advisers Urge Annual Review of Drug Prices
TOKYO (Reuters)—Prime Minister Shinzo Abe’s economic advisers, hoping to curb Japan’s ballooning healthcare costs, proposed on Wednesday reforms to the way drug prices are set, a step opposed by foreign and domestic drug makers who say the changes will stifle investment. The proposals follow a decision to halve the price of Bristol Myers Squibb Co’s…
Smarter Regulation Can Help Cut Drug Prices, Says EU Agency Head
LONDON (Reuters)—Europe’s top drug regulator weighed into the medicine pricing debate on Wednesday, arguing a smarter and faster pharmaceutical approval system was needed to help rein in the spiraling cost of new treatments. In exchange for speeding up the approval process, society would expect manufacturers to charge less for innovative medicines, European Medicines Agency (EMA)…
Americans Want Medicare to Help Negotiate Down Drug Prices
NEW YORK (Reuters)—A vast majority of Americans say the Medicare health program for the elderly should be able to negotiate with drug companies to set lower medication prices, a practice currently prohibited by law, according to a survey released on Friday. The poll conducted by the Kaiser Family Foundation found that 87% of people surveyed…
U.S. to Require Drugmakers to Show Prices in TV Ads
(Reuters)—U.S. Centers for Medicare & Medicaid Services on Wednesday said it will require drugmakers to disclose the list price for their prescription drugs in direct-to-consumer television advertisements, part of the Trump administration’s efforts to lower costs for U.S. consumers. The list price should be included if it is equal to or greater than $35 for…
Pfizer Hikes U.S. Prices of 91 Drugs by Average 20% in 2017
(Reuters)—Pfizer Inc. has hiked the price of nearly a hundred drugs by an average of 20 percent so far this year in the U.S., the Financial Times reported on Friday. The U.S. drug maker raised the list price of 91 medicines—including that of its erectile dysfunction treatment, Viagra, and its pain drug, Lyrica—on June 1…
Pfizer Hikes U.S. Prices for More Than 100 Drugs on Jan. 1
(Reuters)—Pfizer Inc., which plans a $160-billion merger with Ireland-based Allergan Plc to slash its U.S. tax bill, on Jan. 1 raised U.S. prices for more than 100 of its drugs, some by as much as 20%, according to statistics compiled by global information services company Wolters Kluwer. Pfizer confirmed a 9.4% increase for heavily advertised…
Drug Industry Must Address Image Problem over Prices
NEW YORK (Reuters)—Teva Pharmaceutical Industries Ltd’s research chief said on Tuesday the drug industry must act responsibly when it comes to pricing medications, given the mounting anger over the high cost of therapies in the U.S. Democratic presidential candidate Hillary Clinton brought new attention to the issue last week, proposing to cap patients’ treatment costs,…
ACR Expresses Concerns with MedPAC’s Drug Pricing Recommendations
In April, the Medicare Payment Advisory Committee voted to recommend a change in the add-on payment for Part B drugs, including reducing payment for more expensive drugs. The ACR sent a letter to MedPAC expressing concerns about the significant impacts such policies would have on rheumatologists.
CMS Announces Timeline for Drug Negotiations
This month, the CMS will begin steps to develop a drug pricing negotiation process as allowed by the Inflation Reduction Act. The ACR plans to participate in public comment opportunities.
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 24
- Next Page »